Amarin Corp AMRN

NAS: AMRN | ISIN: US0231112063   26/05/2023
1,190 USD (0,00%)
(0,00%)   26/05/2023

12 mei 2023 · Amarin Highlights New Data Providing Potential Mechanistic Insight into Vascepa®/Vazkepa® (Icosapent Ethyl) Reduction of Cardiovascular Events · Persbericht

3 mei 2023 · Amarin Reports First Quarter 2023 Financial Results and Provides Business Update · Persbericht

19 april 2023 · Amarin to Report First Quarter 2023 Financial Results and Host Conference Call on May 3, 2023 · Persbericht

17 april 2023 · Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors · Persbericht

4 april 2023 · Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel's Ministry of Health · Persbericht

16 maart 2023 · Reconstituted Amarin Board Ready for the Challenge of Unlocking True Potential of VASCEPA®/VAZKEPA® (Icosapent Ethyl) · Persbericht

6 maart 2023 · Amarin Highlights New Evidence of Therapeutic Value of EPA in Reducing Cardiovascular Events in At-Risk Patients Presented at ACC.23/WCC · Persbericht

5 maart 2023 · Amarin Announces New REDUCE-IT® Data at ACC.23/WCC Showing Benefit of VASCEPA®/VAZKEPA® (Icosapent Ethyl) in High-Risk Patients with a Recent Acute Coronary Syndrome Event · Persbericht

1 maart 2023 · Amarin Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update · Persbericht

28 februari 2023 · Amarin and CSL Seqirus Announce Exclusive License and Distribution Agreement to Commercialize VAZKEPA® (Icosapent Ethyl) in Australia and New Zealand · Persbericht

27 februari 2023 · Amarin Corporation to Present New Data Evaluating VASCEPA®/VAZKEPA® (Icosapent Ethyl) at ACC.23/WCC · Persbericht

22 februari 2023 · Amarin to Present at Cowen's 43rd Annual Health Care Conference · Persbericht

21 februari 2023 · Amarin to Report Fourth Quarter and Full Year 2022 Financial Results And Host Conference Call on March 1st, 2023 · Persbericht

31 januari 2023 · Amarin Files Definitive Proxy Materials and Mails Letter to Shareholders · Persbericht

27 januari 2023 · Amarin to Present at SVB Securities Global Biopharma Conference · Persbericht

19 januari 2023 · Amarin Responds to Inaccurate and Misleading Statement by Sarissa · Persbericht

11 januari 2023 · Amarin Comments on Sarissa’s Notice to Call a Special Meeting of Amarin Shareholders · Persbericht

10 januari 2023 · Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023 · Persbericht

10 januari 2023 · Amarin Board of Directors Announces Appointment of Murray W. Stewart, DM FRCP · Persbericht

14 december 2022 · Amarin to Present at the 41st Annual J.P. Morgan Healthcare Conference · Persbericht

Mijn selecties